Every earnings call for JUBLPHARMA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
JUBLPHARMA · 6 transcripts · Healthcare · latest Q4 FY26Jubilant Pharmova Limited has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
FY26 Revenue ₹8,280 cr (+14% YoY); FY26 EBITDA ₹1,326 cr (+8% YoY); FY26 EBITDA Margin 15.9% (−1% YoY). Q4 FY26 Revenue grew 19% YoY to ₹2,290 Crores.
Read full transcript & analysisRevenue ₹1,038 cr (+1% YoY); EBITDA ₹153 cr (+29% YoY); EBITDA Margin 14.7%. Overall revenue stood at ₹1,038 crore, a marginal 1.4% YoY increase, with volume growth of 5% despite macro challenges.
Read full transcript & analysisRevenue (TTM) ₹7,000 cr (+13% YoY); EBITDA Margin (TTM) 16.3%; Net Debt ₹2,500 cr. Vision 2030 target set to double revenue to ₹13,500 crores from ₹6,700 crores in FY24.
Read full transcript & analysisRevenue ₹1,553 cr (+18% YoY); Reported EBITDA ₹155 cr (−22% YoY); PAT ₹-16 cr (−131% YoY). Revenue reported at ₹1,553 crore, up 18.5% YoY, driven by Radiopharmacies and Allergy business growth.
Read full transcript & analysisRevenue ₹1,600 cr (−3% YoY); EBITDA ₹232 cr (−33% YoY); EBITDA Margin 14.5%. Revenue stood at ₹1,600 crore, down 3.4% YoY but up 10.2% QoQ.
Read full transcript & analysisRevenue ₹1,452 cr (−11% YoY); EBITDA Margin 14% (−40% YoY); PAT ₹47 cr (−71% YoY). Revenue stood at ₹1,452 Crore, a 11.2% decline YoY from ₹1,635 Crore.
Read full transcript & analysis